Diseases Industry Analysis
Reportbuyer.com helps you stay ahead with advanced reports on Diseases. Information includes Competitive Positioning, Stakeholder Opinions and Future Market Watch.
RSS
previous
| Alzheimer's disease -Technologies, Markets and Companies (JAI00023) Alzheimer's disease remains a challenge in management. With nearly 8 million sufferers from this condition in the seven major markets of the world and anticipated increases in the future. Considerable... | Jun 2013 | £3,500€4,145$5,448 |
| Global Markets for Infectious Disease Treatments (BCC00698) STUDY GOALS AND OBJECTIVES Infectious diseases are one of the major causes of global morbidity and mortality. Viral, bacterial, parasitic and fungal diseases have plagued humankind for centuries, and our attempts... | May 2013 | £3,500€4,145$5,450 |
| PharmaPoint: Chronic Myeloid Leukemia (CML) - Current and Future Players (GDA45636) PharmaPoint: Chronic Myeloid Leukemia (CML) - Current and Future Players Summary GlobalData has released its pharma report, "PharmaPoint: Chronic Myeloid Leukemia (CML) - Current and Future Players". The report is a vital... | May 2013 | £1,925€2,280$2,995 |
| Synribo (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022 (GDA45651) Synribo (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, "Synribo (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022".... | May 2013 | £2,245€2,659$3,495 |
| Sprycel (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022 (GDA45649) Sprycel (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, "Sprycel (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022".... | May 2013 | £2,245€2,659$3,495 |
| Tasigna (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022 (GDA45652) Tasigna (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, "Tasigna (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022".... | May 2013 | £2,245€2,659$3,495 |
| Cardiovascular Health Technology (Spain) - Industry Report (PMW07660) Plimsoll's CARDIOVASCULAR HEALTH TECHNOLOGY (Spain) analysis is the most definitive and accurate study of the CARDIOVASCULAR HEALTH TECHNOLOGY (Spain) sector in 2013. The report (compiled in Spanish language) is split into... | May 2013 | £520€616$809 |
| Alzheimer's Disease Therapeutics and Diagnostics: Global Markets (BCC00699) STUDY GOALS AND OBJECTIVES BCC's goal in conducting this study was to determine the current status of Alzheimer's disease treatments and diagnostics and assess the growth potential of this area over... | May 2013 | £3,500€4,145$5,450 |
| Psoriasis Market Info™ (DMI00001) Psoriasis is a chronic skin disease that is the most prevalent autoimmune disease in the U.S. with as many as 7.5 million Americans affected (2.5% of the population). Psoriasis Market... | May 2013 | £2,535€3,002$3,950 |
| Psoriatic Arthritis Market Info (DMI00002) Psoriatic Arthritis (PsA) is a form of arthritis that is often associated with psoriasis of the skin. Up to 30% of people with psoriasis also develop psoriatic arthritis, which causes... | May 2013 | £2,535€3,002$3,950 |
| Cystic Fibrosis Market Info (DMI00003) Cystic Fibrosis (CF) is a chronic, progressive, life-limiting autosomal recessive genetic disease that affects the lungs, digestive and reproductive systems and sweat glands. The body's ability to move salt and... | May 2013 | £2,535€3,002$3,950 |
| Legionella Control - Industry Report UK (PMS07594) Plimsoll Publishing's UK Legionella Control Analysis provides a detailed overview of the UK Legionella Control market and delivers a comprehensive individual analysis on the top 180 companies, including INTERTEK GROUP... | May 2013 | £350€415$545 |
| Osteoporosis Treatment Drugs Markets in China (AMI00397) China's demand for osteoporosis treatment drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow.... | May 2013 | £1,285£2,570€1,522€3,044$2,000$4,001 |
| Cancer Monoclonal Antibody Partnering Terms and Agreements (CTP00255) 3rd EditionThe Cancer Monoclonal Antibody Partnering Agreements report provides an understanding and access to the cancer monoclonal antibody partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in... | May 2013 | £1,280€1,516$1,995 |
| Consensus Outlook: Prostate Cancer (FWD00100) Competition intensifies in race to the topThe prostate cancer market has experienced substantial changes in the last five years with patent expiries of key compounds and approvals of new novel therapies. The launch of Zytiga (abiraterone... | Apr 2013 | £3,595€4,258$5,596 |
| PharmaPoint: Pediatric Respiratory Syncytial Virus (RSV) Prophylactics - Current and Future Players (GDA45644) PharmaPoint: Pediatric Respiratory Syncytial Virus (RSV) Prophylactics - Current and Future Players Summary GlobalData has released its pharma report, "PharmaPoint: Pediatric Respiratory Syncytial Virus (RSV) Prophylactics - Current and Future Players". The... | Apr 2013 | £1,925€2,280$2,995 |
| MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - Current and Future Players (GDA40866) MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - Current and Future Players Summary Acute coronary syndrome (ACS) consists of two major diseases: myocardial infarction (MI) and unstable angina, with the former... | Apr 2013 | £2,250€2,665$3,500 |
| PharmaPoint: Chronic Myeloid Leukemia (CML) - Italy Drug Forecast and Market Analysis to 2022 (GDA45639) PharmaPoint: Chronic Myeloid Leukemia (CML) - Italy Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, "PharmaPoint: Chronic Myeloid Leukemia (CML) - Italy Drug Forecast and... | Apr 2013 | £3,210€3,802$4,995 |
| PharmaPoint: Chronic Myeloid Leukemia (CML) - Japan Drug Forecast and Market Analysis to 2022 (GDA45640) PharmaPoint: Chronic Myeloid Leukemia (CML) - Japan Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, "PharmaPoint: Chronic Myeloid Leukemia (CML) - Japan Drug Forecast and... | Apr 2013 | £3,210€3,802$4,995 |
| PharmaPoint: Chronic Myeloid Leukemia (CML) - Germany Drug Forecast and Market Analysis to 2022 (GDA45638) PharmaPoint: Chronic Myeloid Leukemia (CML) - Germany Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, "PharmaPoint: Chronic Myeloid Leukemia (CML) - Germany Drug Forecast and... | Apr 2013 | £3,210€3,802$4,995 |
| PharmaPoint: Chronic Myeloid Leukemia (CML) - France Drug Forecast and Market Analysis to 2022 (GDA45637) PharmaPoint: Chronic Myeloid Leukemia (CML) - France Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, "PharmaPoint: Chronic Myeloid Leukemia (CML) - France Drug Forecast and... | Apr 2013 | £3,210€3,802$4,995 |
| PharmaPoint: Chronic Myeloid Leukemia (CML) - Spain Drug Forecast and Market Analysis to 2022 (GDA45641) PharmaPoint: Chronic Myeloid Leukemia (CML) - Spain Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, "PharmaPoint: Chronic Myeloid Leukemia (CML) - Spain Drug Forecast and... | Apr 2013 | £3,210€3,802$4,995 |
| PharmaPoint: Chronic Myeloid Leukemia (CML) - United Kingdom Drug Forecast and Market Analysis to 2022 (GDA45642) PharmaPoint: Chronic Myeloid Leukemia (CML) - United Kingdom Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, "PharmaPoint: Chronic Myeloid Leukemia (CML) - United Kingdom Drug... | Apr 2013 | £3,210€3,802$4,995 |
| PharmaPoint: Chronic Myeloid Leukemia (CML) - United States Drug Forecast and Market Analysis to 2022 (GDA45643) PharmaPoint: Chronic Myeloid Leukemia (CML) - United States Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, "PharmaPoint: Chronic Myeloid Leukemia (CML) - United States Drug... | Apr 2013 | £3,210€3,802$4,995 |
| OpportunityAnalyzer: Idiopathic Pulmonary Fibrosis (IPF) - Opportunity Analysis and Forecasts to 2017 (GDA40893) OpportunityAnalyzer: Idiopathic Pulmonary Fibrosis (IPF) - Opportunity Analysis and Forecasts to 2017 Summary Idiopathic Pulmonary fibrosis (IPF) is a chronic, progressive fibrosing interstitial pneumonia of unknown cause. Limited to the lungs it... | Apr 2013 | £3,850€4,560$5,995 |
